A Clinical Study Provides the First Direct Evidence That Interindividual Variations in Fecal β-Lactamase Activity Affect the Gut Mycobiota Dynamics in Response to β-Lactam Antibiotics

Margot Delavy, Charles Burdet, Natacha Sertour, Savannah Devente, Jean-Denis Docquier, Nathalie Grall, Steven Volant, Amine Ghozlane, Xavier Duval, France Mentré, Christophe d’Enfert, Marie-Elisabeth Bougnoux, on behalf of the PrediRes Study Group

ABSTRACT
Antibiotics disturb the intestinal bacterial microbiota, leading to gut dysbiosis and an increased risk for the overgrowth of opportunistic pathogens. It is not fully understood to what extent antibiotics affect the fungal fraction of the intestinal microbiota, the mycobiota. There is no report of the direct role of antibiotics in the overgrowth in healthy humans of the opportunistic pathogenic yeast Candida albicans. Here, we have explored the gut mycobiota of 22 healthy subjects before, during, and up to 6 months after a 3-day regimen of third-generation cephalosporins (3GCs). Using ITS1-targeted metagenomics, we highlighted the strong intra- and interindividual diversity of the healthy gut mycobiota. With a specific quantitative approach, we showed that C. albicans prevalence was much higher than previously reported, with all subjects but one being carriers of C. albicans, although with highly variable burdens. 3GCs significantly altered the mycobiota composition and the fungal load was increased both at short and long term. Both C. albicans relative and absolute abundances were increased but 3GCs did not reduce intersubject variability. Variations in C. albicans burden in response to 3GC treatment could be partly explained by changes in the levels of endogenous fecal β-lactamase activity, with subjects characterized by a high increase of β-lactamase activity displaying a lower increase of C. albicans levels. A same antibiotic treatment might thus affect differentially the gut mycobiota and C. albicans carriage, depending on the treated subject, suggesting a need to adjust the current risk factors for C. albicans overgrowth after a β-lactam treatment.

IMPORTANCE
Fungal infections are redoubtable healthcare-associated complications in immunocompromised patients. Particularly, the commensal intestinal yeast Candida albicans causes invasive infections in intensive care patients and is, therefore, associated with high mortality. These infections are preceded by an intestinal expansion of C. albicans before its translocation into the bloodstream. Antibiotics are a well-known risk factor for C. albicans overgrowth but the impact of antibiotic-induced dysbiosis on the human gut mycobiota—the fungal microbiota—and the understanding of the mechanisms involved in C. albicans overgrowth in humans are very limited. Our study shows that antibiotics increase the fungal proportion in the gut and disturb the fungal composition, especially C. albicans, in a subject-dependent manner. Indeed, variations across subjects in C. albicans

Editor Joseph Heitman, Duke University
Copyright © 2022 Delavy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Marie-Elisabeth Bougnoux, bougnoux@pasteur.fr.
The authors declare no conflict of interest.
This article is a direct contribution from Christophe d’Enfert, a Fellow of the American Academy of Microbiology, who arranged for and secured reviews by Scott Filler, UCLA, and Iliyan Iliev, Cornell University.
Received 17 October 2022
Accepted 21 October 2022
Published 30 November 2022
burden in response to \(\beta\)-lactam treatment could be partly explained by changes in the levels of endogenous fecal \(\beta\)-lactamase activity. This highlighted a potential new key factor for \(C.\ albicans\) overgrowth. Thus, the significance of our research is in providing a better understanding of the factors behind \(C.\ albicans\) intestinal overgrowth, which might lead to new means to prevent life-threatening secondary infections.

**KEYWORDS** antibiotics, \(Candida\ albicans\), gut mycobiota, healthy individuals, \(\beta\)-lactamases

Interest in the role of the gut microbiota in health and disease is rising (1–4) and the role of antibiotics as major disturbers of the microbiota healthy state has been largely studied (5–8). By killing the resident bacteria of the gut, broad-spectrum antibiotics reduce bacterial diversity in the gastrointestinal (GI) tract and decrease the abundance of beneficial bacteria (5, 7). They also alter the gut microbiota interaction network, thus contributing to the overgrowth of opportunistic pathogens (6, 9). More alarmingly, the prolonged use of antibiotics may promote antibiotic resistance (10). For example, \(\beta\)-lactam exposure can lead to the selection of specific gut bacteria able to produce \(\beta\)-lactamases, enzymes that can hydrolyze \(\beta\)-lactam antibiotics, leading to an overall increase in antibiotic resistance (11, 12).

While the bacterial microbiota is extensively studied, less attention has been paid to the mycobiota—the fungal part of the microbiota—and to the consequences that antibiotic-induced dysbiosis may have on the fungal communities of the gut. It is now well established that fungi can rapidly proliferate in the GI tract of mice after removal of gut bacteria by antibiotics (13). The GI tract of mice is not naturally colonized by the opportunistic pathogen \(Candida\ albicans\) and antibiotics have been used to trigger such colonization (14), suggesting that they clear specific bacteria able to inhibit \(C.\ albicans\) growth in the mouse GI tract (15). Yet, we need more information about the impact of an antibiotic-induced dysbiosis on the healthy human gut mycobiota and specifically \(C.\ albicans\). Because \(C.\ albicans\) systemic infections are responsible for thousands of deaths each year (16) and antibiotics are a well-known risk factor for these infections (17), we need to better understand the mechanisms of \(C.\ albicans\) overgrowth in the human gut, upon antibiotic treatment.

In this work, we prospectively followed two parallel groups of 11 healthy subjects each, before, during, and after they were treated intravenously with either cefotaxime or ceftriaxone, two third-generation cephalosporin (3GC) antibiotics that share a similar activity spectrum (8). We quantified the levels of \(C.\ albicans\) carriage in all subjects and characterized their healthy mycobiota and its variability during the 2-week period preceding antibiotic administration. Then, we analyzed the changes in terms of fungal diversity, fungal burden, community profile, and \(C.\ albicans\) levels, occurring in the mycobiota after antibiotics were administered, both at short and long term. Finally, we monitored the level of fecal \(\beta\)-lactamase activity, which is known to modulate the intensity of the post-3GC intestinal dysbiosis, and we correlated the changes in \(\beta\)-lactamase activity with the impact of 3GCs on \(C.\ albicans\) carriage.

**RESULTS**

The gut mycobiota of healthy subjects is highly dynamic and variable. To study the healthy mycobiota, we used fecal samples collected from each of 22 healthy volunteers at day \(-15 (\text{D15}), -7\) (D7), and \(-1\) (D1), before antibiotic administration (see Materials and Methods). In total, 54 fecal samples (one to three available per subject) were available for analyses.

First, we assessed the fungal load, i.e., the ratio between the fungal DNA concentration and the total fecal DNA (see Materials and Methods). The mycobiota represented a very small fraction of the total microbiota in healthy subjects (median fungal load: \(7.9 \times 10^{-6}\), min: \(6.7 \times 10^{-10}\), max: \(1.5 \times 10^{-3}\), Fig. S1A).

Using ITS1 sequencing, we further characterized the mycobiota composition of the 22 subjects during the 2 weeks preceding 3GC exposure. We identified 233 different
OTUs, 182 OTUs (78.1%) being annotated at the phylum level, 167 (71.7%) at the genus level, and 123 (52.8%) at the species level. Overall, the 167 OTUs annotated at the genus level and the 123 OTUs annotated at the species level represented 99.7% and 91.2% of the total number of sequences, respectively.

Ascomycota was the most abundant phylum (mean relative abundance of 77.9%), followed by Basidiomycota (21.9%; Fig. S1B). Sixty-two fungal genera were identified in at least two samples, with eight reaching a mean relative abundance across subjects above 1% (Fig. S1C). Ninety-five species were identified in at least two samples, nine reaching a mean relative abundance across subjects above 1% (Table 1). The taxa relative abundances were highly variable between individuals and across time (Fig. 1A), with *Galactomyces candidus* being the most disparately represented taxa, with a relative abundance varying from 0% to 99.2% depending on the sample.

We identified a median of only 25 OTUs per sample (min: 5, max: 55, Fig. 1B), corresponding to a median Shannon Index of 1.18 (min: 0.18, max: 2.26, Fig. 1B), reflecting a low richness and evenness within each sample. Unlike this low α-diversity, we observed a high β-diversity, which quantifies the level of dissimilarity between samples, with a median Bray-Curtis dissimilarity index of 0.87 between the subjects (min: 0.02 max: 1.00, Fig. 1C). We also followed the variations occurring overtime during the 2-week period preceding 3GC exposure. The within subjects’ diversity, measured between the samples collected from the same subject at different time, was almost as high as the between subject diversity, with a Bray-Curtis dissimilarity index of 0.75 (min: 0.08, max: 0.99, Fig. 1C; Fig. S2).

Cefotaxime and ceftriaxone exposure increases the fungal load and disturbs the gut mycobiota composition. To measure how much the antibiotic treatment affected the gut mycobiota, we compared its features, including the fungal load, genera and species composition, and *C. albicans* absolute levels, at baseline (D0) with those during and after antibiotics (Fig. 2A). Data collected at −D1 were used as baseline. If missing, −D7 data were used instead (see Fig. S3).

We quantified the levels of fecal *C. albicans* in these volunteers by determining the absolute abundance of *C. albicans* using specific qPCR. We detected *C. albicans* DNA at least once between −D15 and −D1 in 20/21 subjects (95.2%) before 3GC administration. In total, 42/51 samples analyzed were positive for *C. albicans* (82.4%). In these samples, *C. albicans* DNA levels ranged from $2.8 \times 10^{-4}$ to 1.26 ng/g of stool, with a median of $9.4 \times 10^{-3}$ ng/g of stool (Fig. 1D). In comparison, by using ITS1 sequencing data and culture methods, we could detect *C. albicans* in only 16/22 (72.7%; Table 1) and in 7/22 (15.8%) subjects, respectively.

**Cefotaxime and ceftriaxone exposure increases the fungal load and disturbs the gut mycobiota composition.** To measure how much the antibiotic treatment affected the gut mycobiota, we compared its features, including the fungal load, genera and species composition, and *C. albicans* absolute levels, at baseline (D0) with those during and after antibiotics (Fig. 2A). Data collected at −D1 were used as baseline. If missing, −D7 data were used instead (see Fig. S3).

We used two metrics to estimate changes during and after antibiotic administration: the areas under the curve (AUCs) of the mycobiota characteristics’ changes from D0, and the changes from D0 of the mycobiota characteristics, for each subject, at

| Main fungal species                  | Prevalencea |
|-------------------------------------|-------------|
|                                     | Fecal samples (%) | Healthy subjects (%) |
|                                     | (N = 54)      | (N = 22)            |
| *Vanrija humicola*                  | 98.2         | 100.0              |
| *Galactomyces candidus*             | 92.6         | 95.5               |
| *Saccharomyces cerevisiae*          | 88.9         | 95.5               |
| *Candida parapsilosis*              | 88.9         | 95.5               |
| *Penicillium roqueforti*            | 72.2         | 90.9               |
| *Cutaeanotrichosporon curvatum*     | 87.0         | 86.4               |
| *Malassezia restricta*              | 88.8         | 77.3               |
| *Candida albicans*                  | 75.9         | 72.7               |
| *Debaryomyces hansenii*             | 68.5         | 59.1               |

*A species is considered present in a sample if its relative abundance is above 0.1%. A species is considered present in a subject if it is present in at least one sample between −D15 and −D1.

**Table 1:** Prevalence of the main fungal species in healthy subjects and in their fecal samples, estimated by ITS1 sequencing.
different time points between D1 and D180. The first metric allows the aggregation of both the duration of the changes and their amplitude whereas the second allows the detection of more punctual variations.

We observed a general long-term increase of the fungal load in the 22 subjects early after the start of the antibiotic treatment. The fungal load significantly increased
immediately after the start of antibiotics, independently of the antibiotic used, with a positive AUCs for all calculated periods between D0 and D2, and D0 and D90 (Wilcoxon test; *P* values of 0.008, 0.017, 0.040, 0.014, 0.009, 0.005, 0.006, and 0.048, respectively) with a maximal 62.3-fold increase at D2 (min: 0.02, max: 1.8 ×10^4; Wilcoxon test; *P* value of 0.007; Fig. 2B; Fig. S4B; Table S1). No difference was observed between the subjects treated with ceftriaxone and those treated with cefotaxime (Fig. 2B; Table S2).

**FIG 2** Impact of 3-day cefotaxime and ceftriaxone IV treatment on the gut mycobiota of 22 healthy subjects followed for a 6-month period. (A) Study design. (B) Log10 (foldchange [FC]) of the fungal load following ceftriaxone and cefotaxime treatment (gray area). Thin lines represent the subjects, thicker lines represent the medians at each day for each treatment group (blue and green) and for all subjects (black). (C) Main fungal species distribution following ceftriaxone and cefotaxime treatment. (D) Distribution of the relative abundance log10 (FC) AUCs for *Candida albicans*, *Debaryomyces hansenii*, *Penicillium roqueforti*, and *Saccharomyces cerevisiae*, highlighting the duration and the amplitude of the perturbations (*q* value < 0.05, Wilcoxon t-test, false-discovery rate correction. Upper whiskers extend from the hinge to the largest value below 1.5 × the interquartile range, and the lower whiskers extend from the hinge to the smallest value above 1.5 × the interquartile range. (E) Log10 (FC) of *C. albicans* DNA levels following ceftriaxone and cefotaxime treatment (gray area). Thin lines represent the subjects, thicker lines represent the medians at each day for each treatment group (blue and green) and for all subjects (black).
At D15, we observed a slight increase of the number of fungal OTUs, compared with D0 (Wilcoxon test; P value of 0.030; Table S1) but not of the Shannon Index (Wilcoxon test; P value of 0.47), suggesting that the fungal α-diversity is not strongly impacted by the antibiotics. No difference was observed between the subjects treated with ceftriaxone or those treated with cefotaxime, and this for all fungal diversity indices studied (Table S2).

Three genera were significantly impacted by the antibiotics Debaryomyces sp., Penicillium sp., and Saccharomyces sp. (Fig. 5A and B; Table S1). Debaryomyces sp. were significantly decreased immediately after the start of the treatment, with negative AUCs between D0 and D3 (Wilcoxon test; q value of 0.02) and a maximal but not significant 12.5-fold drop at D3 (min: 0.09, max: \(1.7 \times 10^5\), Wilcoxon test; q value of 0.08). Penicillium sp. were also decreased immediately after the start of the treatment, with negative AUCs between D0 and D2 and up to D0 and D7 (Wilcoxon test; q values of 0.01, 0.005, 0.003, and 0.0002, respectively) with a maximal 21.4-fold decrease at D4 (min: 0.81, max: 776.2; Wilcoxon test; q value of 0.0008). On the contrary, Saccharomyces sp. relative abundance was punctually increased at D4 (median: 19.5-fold increase, min: 0.32, max: 169.8), compared with baseline (Wilcoxon test; q value of 0.01), before returning to basal levels. No significant difference between the subjects of the two treatment groups was observed at any day, for all genera tested (Table S2).

In addition, at the species level, four taxa were significantly affected by 3GC treatment: S. cerevisiae, D. hansenii, P. roqueforti, and C. albicans (Fig. 2C; Table S1). D. hansenii was decreased for the period D0 to D3, with a corresponding negative AUC (Wilcoxon test; q value of 0.047; Fig. S4C) and P. roqueforti was punctually reduced after the treatment with a 2.4-fold drop at D1 (min: 0.74, max: \(3.3 \times 10^5\); Wilcoxon test; q value of 0.026; Fig. 2D). In contrast, C. albicans and S. cerevisiae relative abundance displayed a 9.8-fold and 19.5-fold raise at D4, respectively (C. albicans: max: \(1.1 \times 10^5\), min: 0.004; Wilcoxon test; q value of 0.04, S. cerevisiae: max: 169.8, min: 0.32 Wilcoxon test; q value of 0.026; Fig. S4C). As for the genera, no significant difference between the subjects of the two groups was observed for any species (Table S2).

Not only C. albicans relative abundance but also its absolute abundance was punctually increased after antibiotics. Indeed, 3GC administration led to a punctual raise of C. albicans DNA levels on the D0 to D4 period (Wilcoxon test, q value of 0.047; Fig. 2E) and C. albicans DNA levels was subject-dependent. For example, subject 1 displayed an impressive increase of C. albicans DNA, with a maximal 2,521.3-fold raise at D15 whereas C. albicans DNA levels were reduced in subject 12 after the treatment. No difference was observed between the two groups of treatment at any days (Fig. 2E; Table S2).

Change in β-lactamase activity levels as a key parameter for C. albicans overgrowth in the GI tract after third-generation cephalosporin administration. β-lactamase activity was measured in each fecal sample by dosing the NFC-hydrolyzing activity. This activity was heterogeneous between subjects before antibiotics, ranging from 2.40 to 1,240 nmol/min of stool, with no difference between the two groups that received either ceftriaxone or cefotaxime, and this for all fungal diversity indices studied (Table S2).

In addition, at the species level, four taxa were significantly affected by 3GC treatment: S. cerevisiae, D. hansenii, P. roqueforti, and C. albicans (Fig. 2C; Table S1). D. hansenii was decreased for the period D0 to D3, with a corresponding negative AUC (Wilcoxon test; q value of 0.047; Fig. S4C) and P. roqueforti was punctually reduced after the treatment with a 2.4-fold drop at D1 (min: 0.74, max: \(3.3 \times 10^5\); Wilcoxon test; q value of 0.026; Fig. 2D). In contrast, C. albicans and S. cerevisiae relative abundance displayed a 9.8-fold and 19.5-fold raise at D4, respectively (C. albicans: max: \(1.1 \times 10^5\), min: 0.004; Wilcoxon test; q value of 0.04, S. cerevisiae: max: 169.8, min: 0.32 Wilcoxon test; q value of 0.026; Fig. S4C). As for the genera, no significant difference between the subjects of the two groups was observed for any species (Table S2).

Not only C. albicans relative abundance but also its absolute abundance was punctually increased after antibiotics. Indeed, 3GC administration led to a punctual raise of C. albicans DNA levels on the D0 to D4 period (Wilcoxon test, q value of 0.047) with a maximal 2.1-fold increase at D2 (min: 0.03, max: 288.4; Wilcoxon test; P value of 0.02; Fig. 2E), when measured by qPCR. However, this increase of C. albicans DNA levels was subject-dependent. For example, subject 1 displayed an impressive increase of C. albicans DNA, with a maximal 2,521.3-fold raise at D15 whereas C. albicans DNA levels were reduced in subject 12 after the treatment. No difference was observed between the two groups of treatment at any days (Fig. 2E; Table S2).
C. albicans DNA levels were significantly increased in the group “low,” whereas no change was detected in the group “high” (D4: Wilcoxon test; P value of 0.008 and 0.84, respectively; D30: Wilcoxon test; P value of 0.023 and 0.26, respectively; Fig. 3C).

Finally, we showed a highly significant negative interaction between the D0 to D10 AUC of the change in β-lactamase activity and the D0 to D10 AUC of the change in C. albicans DNA levels (Spearman correlation; R: −0.59, P value: 0.009; Fig. 3D). No such correlation could be found between the D0 to D10 AUC of the fungal load and the D0 to D10 AUC of the change in β-lactamase activity (Spearman correlation; R: −0.25, P value: 0.3).

DISCUSSION

In this study, we explored the impact of β-lactam antibiotics on the human gut mycobiota by performing a targeted metagenomic analysis of the mycobiota of healthy subjects before, during, and after 3GC exposure. 3GC strongly affected the
mycobiota, especially *C. albicans* carriage, with wide intersubject variations that were not related to the type of 3CG they received. We identified the changes of fecal β-lactamase activity after treatment as a potential key factor regulating *C. albicans* overgrowth, with subjects characterized by a low increase of β-lactamase activity displaying a stronger increase of *C. albicans* levels following antibiotics. This regulation is likely mediated by a differential impact of antibiotics on the endogenous gut bacteria, according to differences in the occurrence of β-lactamase-producing bacteria in the microbiota. Briefly, a microbiota rich in β-lactamase-producing bacteria would favor 3GC hydrolysis, reduced antibiotic-induced microbiota dysbiosis, and reduced *C. albicans* overgrowth. In contrast, a microbiota poor in β-lactamase-producing bacteria would allow 3GC maintenance, high antibiotic-induced microbiota dysbiosis, and high *C. albicans* overgrowth. This phenomenon may explain the so-called *C. albicans* colonization resistance experienced by some individuals. Such colonization resistance has been the subject of an old and preliminary report (11) but has not been further explored until this present study. Overall, these results are coherent with the hypothesis stating that specific intestinal bacteria or their metabolites regulate *C. albicans* overgrowth (6, 14, 15, 18, 19). Our results attest that the same antibiotic regimen may affect differentially the microbiota and consequently lead to different risks of *C. albicans* overgrowth depending on the subject that receives it. The current paradigm stating that antibiotics are systematically a risk factor for *C. albicans* overgrowth should thus be adjusted for treatments based on β-lactams antibiotics. Monitoring fecal β-lactamase activity during and after a β-lactams antibiotic treatment could be an accurate predictor of the actual risk of a later increase of *C. albicans* burden.

As importantly, we found that *C. albicans* was present, in varying quantity, in the gut of almost every healthy subject. This study is the first to use a qPCR method to quantify and follow *C. albicans* carriage, allowing an increasingly specific detection. Using more traditional assays, the prevalence of *C. albicans* in these subjects was much lower and close to what has been previously reported (20–22). This suggests that our results reflect the reality of what is the true presence of *C. albicans* in the gut of healthy humans. If confirmed in a larger study, this might indicate that *C. albicans* is not a facultative commensal as previously thought, but that it is able to maintain itself in the gut of most individuals, even at very low concentration.

That almost all subjects in this study were colonized by *C. albicans* renders our cohort particularly adapted to follow the effects of antibiotic treatment on *C. albicans* carriage. Moreover, contrary to what has been done in other studies (6), our focus on a single antibiotic family allows a precise understanding on how 3GC, a largely used antibiotics family, acts on the human gut mycobiota. This allowed us to show that 3GC strongly affect the gut mycobiota, with a global increase of the fungal load, as well as a punctual perturbation of several fungal species and genera, including *C. albicans*. Indeed, both *C. albicans* relative and absolute abundances were increased after the start of antibiotics. This is particularly concerning since a recent report showed that the administration of β-lactam antibiotics leads to increased virulence of *C. albicans* (23). By killing Gram-negative commensal bacteria, β-lactams cause the release of a large amount of peptidoglycans, which can then induce *C. albicans* hyphal growth, an essential virulence factor of this species (23). Moreover, a recent study showed that exposure to non-3GC broad-spectrum antibiotics not only promotes susceptibility to *C. albicans* systemic infection in mice, but also increases the mortality, through an impairment of the lymphocyte-dependent IL-17A- and GM-CSF-mediated response (24). Therefore, *C. albicans* cannot only growth in patients treated with 3GCs, but its disruptive abilities might also be increased. This can be particularly problematic, not only for immunosuppressed patients, but also for those with inflammatory bowel disease that are already carrying higher levels of *C. albicans* (25, 26) in their gut.

Overall, most of the mycobiota perturbations following 3GC treatment were subject-dependent, with some subjects more impacted than others. This is not particularly surprising considering the within- and between-subjects Bray-Curtis dissimilarity observed.
pretreatment. This has already been reported (21) and suggests that the largest part of the fecal mycobiota is made of transient species brought by the diet, such as *D. hansenii*, which is commonly found in cheese (27), or potentially by the respiration of spores of filamentous fungi, which can then be swallowed, such as *Penicillium* sp. This hypothesis is supported by a recent study showing that diet-associated fungi are recovered with low relative abundances in mucosal surgical-recovered samples, highlighting the differences observed in the gut mycobiota depending on its spatial organization across the GI tract (28). Moreover, associated fungi strongly contribute to the fungal biomass of the fecal microbiota (29). Our results would also indicate that contrary to *Penicillium* sp. or *D. hansenii*, *C. albicans* main reservoir is indeed humans, which would explain why an environmental reservoir for this species has yet to be found (18, 30, 31).

Finally, fungi represented only a small fraction of the total microbiota based on total and fungal DNA quantification. This underrepresentation of the fungal community in the human gut has already been reported (32), but the authors did not quantify the exact proportion of the mycobiota. More recently, the fungal load of 24 healthy subjects was estimated, with results very similar to ours (33). Finally, Doron et al. confirmed that the fungal biomass was low within the gut microbiota, representing only 1% to 2% of the microbial biomass of the gut (29). However, to our knowledge, this present study is the first to assess the day-to-day variation of the fungal load in healthy individuals.

Taken together, this study offers a better understanding of the factors behind *C. albicans* overgrowth after antibiotics. We showed that a same antibiotic treatment may disturb differentially the gut microbiota, depending on the subject that receives it. This highlights the importance of a more personalized use of antifungal prophylaxis, and helps limiting the selection of fungi resistant to antifungal drugs in patients at high risk of invasive candidiasis, such as intensive care unit or haemat-oncology patients.

**MATERIALS AND METHODS**

**CEREMI cohort.** In this study, we used fecal samples from the CEREMI study, a prospective, open-label, and randomized clinical trial conducted from March 2016 to August 2017 in healthy adult subjects at the Clinical Investigation Center at Bichat-Claude Bernard Hospital (Paris, France) (8). Participants were given oral and written information and had to return signed consent before inclusion in the trial. For more information about the clinical trial, see Burdet et al. (8).

The 22 included subjects were randomized in a 1:1 ratio and were treated for 3 days with either ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h). 3GC were administered as a 30-min intravenous infusion using an automatic high-precision infusion pump.

Fecal samples were collected before treatment at −D15, −D7, and −D1; during treatment at D1, D2, and D3; and after treatment at D4, D7, D10, D15, D30, D90, and D180. Fecal samples were stored at −80°C.

**Fungal DNA extraction from fecal samples.** For each sample, 250 mg of stool was processed following the repeated bead beating plus column method described by Yu and Morrison (34), except than a FastPrep-24 device (MP Biomedicals, Belgium) was used instead of a Mini-Beadbeater. Total fungal DNA levels were measured by Qubit (Invitrogen, USA) using the dsDNA Broad Range Kit (Invitrogen, USA). Samples for which this concentration was below 50 ng/µL were excluded from the analysis.

**ITS1 sequencing.** We prepared amplicon libraries, targeting the ITS1 region, using ITS1F and ITS2 primers (35, 36). Amplicon were generated by PCR using a 96-well thermal cycler in the following conditions: 95°C for 3 min, 25 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, and 72°C for 5 min, and cooling at 4°C. Amplicons were purified with AMPure XP (Beckman Coulter, USA) as described in the 16S Metagenomic Sequencing Library Preparation guide (37). Adapter were attached using Nextera XT Index Kit (Illumina, France) and the index PCRs were performed in the following conditions: 95°C for 3 min, eight cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, and 72°C for 5 min, and cooling at 4°C. Barcoded PCR products were purified with AMPure XP (Beckman Coulter, USA) and verified and quantified on a Bioanalyzer DNA 1000 chip (Agilent, USA). Samples were normalized at 4 nM and pooled into a library, using 5 µL of each diluted sample. A PhiX sequencing control was prepared following the manufacturer’s instructions. The libraries were sequenced in 300-bp paired-end using the MiSeq reagent kit V3 on Illumina MiSeq platform (Illumina, Evry, France).

**OTU building process and taxonomic assignment.** We recovered 8,819,635 amplicons from ITS1 region. After removal of singletons and chimera amplicons using the SHAMAN pipeline (38), we clustered the 56,634 remaining amplicons in OTUs using a cut-off value of 97% similarity. Thus, 4,648 OTUs were obtained and 551 of them could be aligned against fungal sequences of the UNITE database. On
these 551 fungal OTUs, 340 were present in at least two fecal samples and were conserved for the downstream analyses. We performed a first round of annotation on SHAMAN against the UNITE database (rev. 8.0) and then a second round against a more recent release of UNITE (rev. 8.2). The OTUs we could not annotate were submitted to a classic BLASTN. Only hits matched with a similarity above 97% to reference genomes were conserved. The abundances and weighted non-null normalized counts tables were generated with SHAMAN (38).

**Quantitative PCR for detection of total fungal load in human DNA samples.** Fungal DNA was quantified by TaqMan qPCR as described by Liu et al. (39) using a double dye MGB 5’-6-FAM-labeled probe (Eurogentec, Belgium). All reactions were performed on a CFX96 real-time PCR system (Bio-Rad, USA) with the following conditions: 2 min at 50°C, 10 min at 95°C, 15 s at 95°C, and 1 min at 65°C, the last two steps repeated for 45 cycles. All samples were tested in two independent rounds, each time in duplicates.

The fungal load was estimated by dividing the fungal DNA concentration by the total DNA concentration of the sample (33), obtained by Qubit Broad Range protocol.

**Quantitative PCR for detection of C. albicans DNA in human DNA samples.** At 1:10 dilution, 7.5 µL of the extracted total fecal DNA were used as a template for TaqMan qPCR analysis, using probes and primers described by Guiver et al. (40), at 0.1 µM and 0.2 µM, respectively. All reactions were performed on a CFX96 real-time PCR system (Bio-Rad, USA) with the following conditions: 2 min at 50°C, 10 min at 95°C, 15 s at 95°C, and 1 min at 62°C; the last two steps repeated for 45 cycles. All samples were tested in two independent rounds, each time in duplicates.

**Quantitative PCR amplification control.** To exclude the presence of qPCR inhibitors, samples diluted at 1:10, were submitted to the Universal Exogenous qPCR Positive Control for TaqMan Assay (Eurogentec, Belgium), using a Cy5-QXL 670 Probe system (Eurogentec, Belgium). Manufacturer’s recommendations were followed.

**Culture of the fecal samples.** A 10-µL loop of fecal samples was mixed with 100 µL H2O and plated on a Candida CHROMAGAR medium plate (bioMérieux, France). Potential C. albicans colonies were further tested by MALDI-TOF MS (Brucker, USA) to confirm the identification.

**Measure of the β-lactamase activity.** Fecal β-lactamase activity was quantified by measuring the hydrolysis of nitrocephin, a chromogenic cephalosporin. Activity was measured at least in duplicate.

Fecal samples (stored at 65°C) were thawed 30 min on ice. Then, 140 mg to 380 mg of each fecal sample was mixed with 5 mL/g of stool HZn buffer (50 mM (2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, pH 7.5, supplemented with 50 µM ZnSO4) and agitated for 1 h. Samples were centrifuged twice at 4°C (15 min and 30 min). Then, 3 to 20 µL of the obtained supernatant were mixed with 100 µM nitrocefin (Cayman Chemical, USA) and HZn buffer to reach a final volume of 200 µL. Samples were incubated 20 min at room temperature in a 1:1 ratio with HZn buffer. Nitrocefin hydrolysis was monitored in EnVision microplate reader (Perkin Elmer, USA) at 482-nm wavelength. SpectraPlate-96 (Perkin Elmer, USA) using an automated liquid handling Janus Integrator system (Perkin Elmer, USA) was used to conduct the assays.

β-lactamase activity was normalized to one gram of fecal sample and to 1-cm pathlength. Detection threshold was set at a cut-off value of 4.8 nmol/min-g of fecal sample.

**Biostatistical analyses.** All analyses were performed on R (version 4.0.2 [41]). We used the vegan package (v.2.5-6 [42]) to compute diversity indexes and ggplot2 package to generate the figures (v. 3.3.5 [43]).

We used samples collected at −D1 before treatment as baseline, called D0. If this sample was missing, sample collected at −D7 before treatment was used instead. If both samples were missing, sample collected at −D15 before treatment was used as D0 sample.

We calculated the change from baseline of the fungal load, C. albicans DNA absolute abundance, the relative abundance of the fungal genera, and species and β-lactamase activity. Null values were replaced by the minimal non-null value of the given variables divided by two, to allow a log10 transformation. Only the fungal genera and species reaching a maximal relative abundance superior to 1% for at least half of the subjects were analyzed. We calculated the AUCs using the R package MESS (v. 0.5.7, [44]) for each period from D0 to D2 up to D0 to D180 based on the normalized changes from baseline and the actual time and date of stool collection.

For all analyses, we used bilateral nonparametric Wilcoxon exact tests. We used a type I error of 0.05 and corrected the P values for multitesting using false discovery rate correction.

**Data availability.** The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1**, TIF file, 1.6 MB.

**FIG S2**, TIF file, 1 MB.

**FIG S3**, TIF file, 0.9 MB.

**FIG S4**, TIF file, 2 MB.

**TABLE S1**, XLSX file, 0.02 MB.

**TABLE S2**, XLSX file, 0.02 MB.
ACKNOWLEDGMENTS

This work was supported by grants from Agence Nationale de la Recherche (FunComPath ANR-14-FEC-0004 and PrediRes ANR-16-CE15-0022); the French Government’s Investissement d’Avenir program (Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases [ANR10-LABX-62-IBEID]); the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie action, Innovative Training Network (FunHoMic; Grant No. 812969) and Assistance Publique – Hôpitaux de Paris (CEREMI CRC13-179).

We thank Antoine Andremont and David Skurnik for the fruitful discussions.

We thank the Institut Pasteur Biomics platform (Marc Monot and Laurence Motreff) and the Institut Pasteur Bioinformatics and Biostatistics Hub for their help for generating and analyzing the sequencing data.

For the PrediRes study group: Charles Burdet (INSERM, Université de Paris APHP-Bichat Hospital), Erick Denamur (INSERM, Université de Paris), Xavier Duval (INSERM, Université de Paris, APHP-Bichat Hospital), Dusko Ehrlich (INRA Metagenopolis), France Mentré (INSERM, Université de Paris, APHP-Bichat Hospital), Eduardo P. C. Rocha (Institut Pasteur), Laurie Alla (INRA Metagenopolis), Emmanuelle Lechatetier (INRA Metagenopolis), Florence Levenez (INRA Metagenopolis), Nicolas Pons (INRA Metagenopolis), Benoît Quinquis (INRA Metagenopolis), Khadija Bourabha (INSERM), Antoine Bridier Nahmias (INSERM, Université de Paris), Olivier Clermont (INSERM, Université de Paris), Mélanie Magnan (INSERM, Université de Paris), Olivier Tenaillon (INSERM, Université de Paris), Camille d’Humières (INSERM, Université de Paris, APHP-Bichat Hospital, Institut Pasteur), Amandine Perrin (Institut Pasteur), Marie Touchon (Institut Pasteur), Dominique Rainteau (INSERM, Université Pierre et Marie Curie, APHP – Saint Antoine Hospital), Farid Ichou (ICAN), Philippe Lesnik (ICAN), Jimmy Mullaert (INSERM, Université de Paris, APHP – Bichat Hospital), Thu Thuy Nguyen (INSERM).

REFERENCES

1. Krajmalnik-Brown R, Lozupone C, Kang D-W, Adams JB. 2015. Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease. Microb Ecol Heal Dis 26.
2. Milani C, Ticinesi A, Gerritsen J, Nouvenne A, Lugli GA, Mancabelli L, Tarnawski A, Puccetti P, Mancinelli R. 2016. Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.00820-19.
3. Zuo T, Zhang F, Li GY, Yeoh YK, Zhan H, Wang Y, Chung ACK, Ching CP, Chen N, Lai CK, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS, Ng SC. 2020. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 159:944–955.e8. https://doi.org/10.1053/j.gastro.2020.05.048.
4. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JJ. 2007. The Human Microbiome Project. Nat 449:804–810. https://doi.org/10.1038/nature06244.
5. Burdet C, Nguyen TT, Duval X, Ferreira S, Andremont A, Guedj J, Mentré F, Ait-Illane B, Alavoine L, Duval X, Ecobichon JI, Ilic-Habenscu E, Laparra A, Nisus ME, Raillaz M, Sindrilaru V, Chachaty E, the DAV132-CL-1002 Study Group. 2019. Impact of antibiotic gut exposure on the temporal changes in microbiome diversity. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.00820-19.
6. Seelbinder B, Chen J, Brunke S, Vazquez-Uribe R, Santhaman R, Meyer AC, De Oliveira Lino FS, Chan KF, Imamovic L, Tsang CC, Lam RPK, Stirling S, Humières C, Tenaillon O, Denamur E, Magnan M, Tancrede C. 2019. Ceftriaxone and ceftazidime have similar effects on the intestinal microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.00820-19.
